SCHEMBL167312

SCHEMBL167312

COC(=O)c1cc(Br)c(C)cc1OCc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.49
HPGD P15428 1/20 0.49
MCL1 Q07820 1/20 0.47
L3MBTL1 Q9Y468 3/20 0.47
SMPD1 P17405 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
FFAR4 Q5NUL3 2/20 0.46
POLB P06746 2/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
MAPT P10636 1/20 0.46
RAB9A P51151 1/20 0.46
LRRK2 Q5S007 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
CYP1A2 P05177 1/20 0.45
CYP2C19 P33261 1/20 0.45
FOLH1 Q04609 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28437033 0.90 SMPD1 (0.50) LMNAHPGDL3MBTL1SMPD1HDAC1
SCHEMBL646463 0.89 ABCB1 (0.53) LMNAHPGDL3MBTL1SMPD1HDAC1
SCHEMBL165982 0.89 MCL1 (0.57) MCL1L3MBTL1TDP1FFAR4POLB
SCHEMBL12939114 0.86 TDP1 (0.56) MCL1L3MBTL1TDP1FFAR4MEN1
SCHEMBL1976781 0.86 FFAR4 (0.51) LMNAHPGDL3MBTL1SMPD1HDAC1
SCHEMBL21327288 0.85 LMNA (0.52) LMNAHPGDMCL1L3MBTL1SMPD1
SCHEMBL16616227 0.85 SMN1; SMN2 (0.55) LMNAHPGDKMT2AMAPTSMN1; SMN2
SCHEMBL1764051 0.84 ABCB1 (0.59) LMNAHPGDL3MBTL1SMPD1HDAC1
SCHEMBL31565068 0.84 FFAR4 (0.49) LMNAHPGDMCL1L3MBTL1SMPD1
SCHEMBL16388506 0.84 SMN1; SMN2 (0.51) HPGDMCL1L3MBTL1TDP1FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9365551-B2 2-(benzyloxy) benzamides as LRRK2 kinase inhibitors GLAXO GROUP LIMITED (GB) 2016-06-14 US disclosed
EP-2611772-B1 2-(BENZYLOXY)BENZAMIDES AS LRRK2 KINASE INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2014-09-24 EP disclosed
US-20130225584-A1 2-(BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-08-29 US disclosed
EP-2611772-A1 2 - (BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS GlaxoSmithKline Intellectual Property Development Limited (GB) 2013-07-10 EP disclosed
WO-2012028629-A1 2 - (BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225584-A1 2-(BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS LRRK2, PARK7, BRSK2 LMNA 1687/4885HPGD 3234/4885MCL1 2828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.